Last reviewed · How we verify

Abnormal uterine bleeding due to uterine fibroid — Treatment Landscape & Competitive Intelligence

Abnormal uterine bleeding due to uterine fibroid (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Abnormal uterine bleeding due to uterine fibroid, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Orgovyx relugolix MYOVANT SCIENCES Gonadotropin Releasing Hormone Receptor Antagonist [EPC] Gonadotropin-releasing hormone receptor 2020-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. MYOVANT SCIENCES · 1 drug in Abnormal uterine bleeding due to uterine fibroid

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Abnormal uterine bleeding due to uterine fibroid:

Cite this brief

Drug Landscape (2026). Abnormal uterine bleeding due to uterine fibroid — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/abnormal-uterine-bleeding-due-to-uterine-fibroid. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing